Mesoblast develops cell therapies for inflammatory diseases, led by Ryoncil, approved in the US for a transplant complication in children. It last closed at $11.91 on Nov 17, down 4.34% on the day. MESO last reported earnings on Thu, Feb 26, 2026.
From MESO's SEC filings, latest 20-F for the period ending Dec 31, 2025 (filed Aug 27). Last 12 months adds up the four latest quarters. Per share figures are left out because the US listing can represent a different number of shares.
Only 1 firm rated MESO in the past 90 days, not enough for a consensus
Average 12-month target
$39.00
▲ 227.5% upside
Based on 1 analyst who set a price target on MESO in the past 90 days. The average target is $39.00, with a high of $39.00 and a low of $39.00, compared with the last close of $11.91.
Highest target$39.00
Average target$39.00
Lowest target$39.00
Latest rating changes
Piper SandlerReiterated
Aug 27Buy$39
Date
Firm
Action
Rating
Price target
Aug 27
Piper Sandler
Reiterated
Buy
$39
Loading…
Technical Analysis
MESO · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold
The stock is 14% below its 20 day and 19% below its 50 day average. It is 27% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 35), near oversold. The nearest support is the swing low (Oct 19) at $11.89, and the nearest resistance the Pivot at $12.02.
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 5.5%/day
Key levels
$21.5052 week high+80.5%
$15.16200 day average+27.3%
$15.06100 day average+26.4%
$14.47Swing high (Oct 12)+21.5%
$14.1350 day average+18.6%
$13.6120 day average+14.3%
$12.31Pivot R1+3.4%
$12.02Pivot+0.9%
$11.91Last close
$11.89Swing low (Oct 19)−0.2%
$11.7452 week low−1.4%
$11.63Pivot S1−2.4%
Indicators
RSI (14)
35.02
Weak, oversold below 30
Neutral
MACD
-0.35
Below its signal line
Bearish
Stochastic
6.1
Near the bottom of its range
Oversold
ADX (14)
17.1
No clear trend
Williams %R
-95.8
Oversold below −80, overbought above −20
Oversold
CCI (20)
-121.8
Oversold below −100, overbought above 100
Oversold
Rate of change
−19.4%
Change over 10 sessions
Bearish
ATR (14)
$0.65
Typical daily range, 5.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Falling
Short trendBearish
Long trendNot enough history
MomentumWeak
StretchNormal
VolatilityNormal, 14.2%/day
Key levels
$21.5052 week high+80.5%
$15.16200 day average+27.3%
$15.06100 day average+26.4%
$14.47Swing high (Oct 12)+21.5%
$14.1350 day average+18.6%
$13.6120 day average+14.3%
$12.31Pivot R1+3.4%
$12.02Pivot+0.9%
$11.91Last close
$11.89Swing low (Oct 19)−0.2%
$11.7452 week low−1.4%
$11.63Pivot S1−2.4%
Indicators
RSI (14)
39.54
Weak, oversold below 30
Neutral
MACD
-0.64
Below its signal line
Bearish
Stochastic
20.3
Middle of its range
Neutral
ADX (14)
15.7
No clear trend
Williams %R
-97.4
Oversold below −80, overbought above −20
Oversold
CCI (20)
-153.9
Oversold below −100, overbought above 100
Oversold
Rate of change
−23.1%
Change over 10 sessions
Bearish
ATR (14)
$1.69
Typical daily range, 14.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200–
What happened before, for MESO
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how MESO did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow MESO usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How MESO has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2009.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MESO is in one of them and how their past MESO trades turned out.
Mesoblast is a biotechnology company based in Melbourne, Australia, that develops cell therapies made from mesenchymal cells taken from healthy adult bone marrow. Its lead product, Ryoncil, is approved in the United States to treat a severe complication of bone marrow transplants in children and is sold to physicians at transplant centers. The company is also developing these cells for other inflammatory conditions, including chronic low back pain and heart failure. The cells can be given without donor matching and are produced at industrial scale.